What is it about?
• WHAT IS CURRENT KNOWLEDGE Helicobacter pylori (HP) infection has become more and more resistant to conventional first-line treatment regimens. So, there is a considerable interest in evaluating new antibiotic combinations and regimens.
Featured Image
Why is it important?
• WHAT IS CURRENT KNOWLEDGE Helicobacter pylori (HP) infection has become more and more resistant to conventional first-line treatment regimens. So, there is a considerable interest in evaluating new antibiotic combinations and regimens. • WHAT IS NEW HERE? Nitazoxanide is an anti-infective drug with demonstrated activity against protozoa and anaerobic bacteria including HP. This work is designed to evaluate the efficacy and safety of a unique triple nitazoxanide based regimen as a treatment regimen in Egyptian patients with HP infection.
Perspectives
The present results could state that Nitazoxanide can safely and effectively overcome the problem of H.pylori resistance in Egypt Delta to metronidazole therapy. As well in combination with clarithromycin has a higher efficacy than the summation of levofloxacin and doxycycline (LOND) in H.pylori Egyptian patients in the delta region.
sherief Abd-Elsalam
Tanta University
Read the Original
This page is a summary of: Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori
infection, Helicobacter, May 2017, Wiley,
DOI: 10.1111/hel.12395.
You can read the full text:
Contributors
The following have contributed to this page
